A tighter archive for life-science signals.
Search once, then narrow by source or topic.
FDA clears Encora Therapeutics’ wearable wrist device for essential tremor
FDA clears Encora Therapeutics’ wearable wrist device for essential tremor
What were the biggest clinical trial flops of 2025?
What were the biggest clinical trial flops of 2025?
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
Chutes & Ladders—Sanofi's stunning CEO switch
Chutes & Ladders—Sanofi's stunning CEO switch
Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site
Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site
Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
'When the markets opened, we were ready': Why biotech IPOs are back for 2026
'When the markets opened, we were ready': Why biotech IPOs are back for 2026
Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance
Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance
Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3
Langer-backed biotech looks to end cancer recurrence with surgical revolution
Langer-backed biotech looks to end cancer recurrence with surgical revolution
Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
Seres to lay off 30% of employees, pause lead program in latest strategic shift
Seres to lay off 30% of employees, pause lead program in latest strategic shift
Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
European VCs join forces to boost flagging biotech investment in the region
European VCs join forces to boost flagging biotech investment in the region
UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing
UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing
Takeda downsizes Boston footprint amid consolidation effort
Takeda downsizes Boston footprint amid consolidation effort
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page